Equities

Invion Ltd

Invion Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.006
  • Today's Change0.00 / 0.00%
  • Shares traded50.00k
  • 1 Year change-14.29%
  • Beta1.0006
Data delayed at least 20 minutes, as of Apr 24 2024 03:20 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Invion Limited is an Australia-based life sciences company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is engaged in the clinical development of a PhotoDynamic Therapy (PDT) for cancer. Its photosensitizer (the agent used in PDT) is called IVX-PDT and is based on Photosoft Technology. Its PDT is an alternative to surgery, and in contrast to radiotherapy and chemotherapy, which are immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumor by leukocytes. It produces topical and intravenous products suitable for use in skin cancer and in solid tumors, such as those present in ovarian, prostate and lung cancer. It is developing a topical formulation of its photosensitizing agent, IVX-PDT, to treat superficial Basal Cell Carcinoma (sBCC), Actinic Keratosis (AK) and Squamous Cell Cancer (SCC).

  • Revenue in AUD (TTM)4.46m
  • Net income in AUD-1.50m
  • Incorporated2000
  • Employees8.00
  • Location
    Invion Ltd100 Albert Road, South MelbourneMELBOURNE 3205AustraliaAUS
  • Phone+61 39692-7222
  • Fax+61 73295-0599
  • Websitehttps://inviongroup.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immuron Ltd3.58m-3.88m23.94m6.00--1.36--6.69-0.017-0.0170.01570.07690.16640.64687.92596,106.70-18.06-27.48-19.86-29.5880.8777.52-108.52-296.647.79-2.850.0023--135.85-13.34-32.66--3.27--
BCAL Diagnostics Ltd3.67m-5.00m23.97m----3.94--6.52-0.0227-0.02270.01660.02410.4493--3.21---61.10-54.01-67.83-62.57-----136.00-248.64---131.830.1985--298.6363.18-49.51--91.62--
BPH Energy Ltd345.67k894.65k24.15m2.00k22.451.09--69.850.0010.0010.00040.02030.0177--5.97--4.58-6.894.78-7.7256.39--258.50-357.76----0.0043--96.545.21179.13------
Chimeric Therapeutics Ltd0.00-11.31m24.70m----1.52-----0.027-0.0270.000.01910.00-------45.96---69.36-------------10.010.1596-------60.40------
LBT Innovations Limited2.00m-21.38m25.41m17.00--9.38--12.68-0.0428-0.04280.00380.0020.10870.08192.25117,882.40-115.89-28.85-131.86-30.9994.76---1,066.62-441.763.30-6.850.5633---5.29-18.45-239.17---34.63--
Cann Group Ltd16.45m-29.28m27.12m40.00--0.5339--1.65-0.0724-0.07240.04060.11610.12370.39527.37---22.03-22.28-34.23-24.4321.11---178.07-407.570.0861-5.880.5646--114.9089.76-27.66---11.16--
Lumos Diagnostics Holdings Ltd12.67m-13.60m27.43m----1.93--2.17-0.0366-0.03660.0360.02960.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
Alterity Therapeutics Ltd123.46k-12.28m31.43m11.00--0.9541--254.56-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
IDT Australia Limited10.36m-6.55m34.09m156.00--1.48--3.29-0.022-0.0220.0350.06560.37412.393.51---23.64-9.87-26.41-11.5776.3884.42-63.19-24.942.81--0.0907---42.03-11.97-632.59---26.04--
Cynata Therapeutics Ltd436.25k-13.65m37.72m0.00--3.07--86.47-0.0873-0.08730.00270.06830.0257--4.26---80.33-38.07-87.15-41.10-----3,127.93-513.73----0.00---94.9619.81-162.20------
Invion Ltd4.46m-1.50m38.55m8.00--2.16--8.64-0.0002-0.00020.00070.00280.2345--3.20---7.88-16.93-8.12-18.13-----33.60-51.63----0.00--25.7241.1827.95------
Little Green Pharma Ltd23.24m-3.14m39.23m----0.483558.711.69-0.011-0.01260.08330.26890.2631.1312.06---3.55---4.01--51.02---13.51--2.03-21.270.0667--------------
Prescient Therapeutics Ltd697.94k-7.74m46.71m3.00--2.07--66.92-0.0098-0.00980.00090.02810.0276--2.32---30.58-27.61-32.59-29.03-----1,109.58-3,284.78---412.910.00--939.1629.68-36.88------
Inoviq Ltd751.54k-6.51m49.23m85.00--2.94--65.51-0.0708-0.07080.00820.1820.03392.100.873---29.33-47.68-32.18-50.7695.07---866.27-2,527.824.93--0.0332--119.59153.3150.71------
Anteotech Ltd526.75k-11.46m55.39m40.00--10.63--105.16-0.0056-0.00560.00030.00220.0552--2.62---120.11-68.55-145.22-75.44-----2,176.15-1,432.10----0.1729---46.6511.41-18.08--25.84--
Data as of Apr 24 2024. Currency figures normalised to Invion Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.